These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9666457)

  • 1. Biochemical and biological analyses of farnesyl-protein transferase inhibitors.
    Kohl NE; Koblan KS; Omer CA; Oliff A; Gibbs JB
    Methods Mol Biol; 1998; 84():283-91. PubMed ID: 9666457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
    Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
    Anthony NJ; Gomez RP; Schaber MD; Mosser SD; Hamilton KA; O'Neil TJ; Koblan KS; Graham SL; Hartman GD; Shah D; Rands E; Kohl NE; Gibbs JB; Oliff AI
    J Med Chem; 1999 Aug; 42(17):3356-68. PubMed ID: 10464022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
    Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
    J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clavaric acid: a triterpenoid inhibitor of farnesyl-protein transferase from Clavariadelphus truncatus.
    Jayasuriya H; Silverman KC; Zink DL; Jenkins RG; Sanchez M; Pelaez F; Vilella D; Lingham RB; Singh SB
    J Nat Prod; 1998 Dec; 61(12):1568-70. PubMed ID: 9868169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyl protein transferase inhibitory components of Polygonum multiflorum.
    Kwon BM; Kim SH; Baek NI; Lee SI; Kim EJ; Yang JH; Chae BS; Lee JH; Park HW; Park JS; Kim DK
    Arch Pharm Res; 2009 Apr; 32(4):495-9. PubMed ID: 19407965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of farnesyl-protein-transferase in neuroblastoma cells by alpha-hydroxyfarnesylphosphonate.
    Girgert R; Hohnecker A; Wittrock J; Schweizer P
    Anticancer Res; 1999; 19(4B):2959-62. PubMed ID: 10652579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
    Nørgaard P; Law B; Joseph H; Page DL; Shyr Y; Mays D; Pietenpol JA; Kohl NE; Oliff A; Coffey RJ; Poulsen HS; Moses HL
    Clin Cancer Res; 1999 Jan; 5(1):35-42. PubMed ID: 9918200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyl-derived inhibitors of ras farnesyl transferase.
    Kang MS; Stemerick DM; Zwolshen JH; Harry BS; Sunkara PS; Harrison BL
    Biochem Biophys Res Commun; 1995 Dec; 217(1):245-9. PubMed ID: 8526918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current progress on farnesyl protein transferase inhibitors.
    Singh SB; Lingham RB
    Curr Opin Drug Discov Devel; 2002 Mar; 5(2):225-44. PubMed ID: 11926129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kampanols: novel Ras farnesyl-protein transferase inhibitors from Stachybotrys kampalensis.
    Singh SB; Zink DL; Williams M; Polishook JD; Sanchez M; Silverman KC; Lingham RB
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2071-6. PubMed ID: 9873488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyl transferase inhibitors: current developments and future perspectives.
    Eskens FA; Stoter G; Verweij J
    Cancer Treat Rev; 2000 Oct; 26(5):319-32. PubMed ID: 11006134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxamic acid-based bisubstrate analog inhibitors of Ras farnesyl protein transferase.
    Patel DV; Young MG; Robinson SP; Hunihan L; Dean BJ; Gordon EM
    J Med Chem; 1996 Oct; 39(21):4197-210. PubMed ID: 8863797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Three dimensional quantitative structure-activity relationship of a series of benzocylohepatpyridine farnesyltransferase inhibitors].
    Wan SB; Yi X; Guo ZR
    Yao Xue Xue Bao; 2002 Apr; 37(4):257-62. PubMed ID: 12579819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and selective farnesyl transferase inhibitors.
    Millet R; Domarkas J; Houssin R; Gilleron P; Goossens JF; Chavatte P; Logé C; Pommery N; Pommery J; Hénichart JP
    J Med Chem; 2004 Dec; 47(27):6812-20. PubMed ID: 15615530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyltransferase inhibitors versus Ras inhibitors.
    Gibbs JB; Graham SL; Hartman GD; Koblan KS; Kohl NE; Omer CA; Oliff A
    Curr Opin Chem Biol; 1997 Aug; 1(2):197-203. PubMed ID: 9667853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
    Lombardo LJ; Camuso A; Clark J; Fager K; Gullo-Brown J; Hunt JT; Inigo I; Kan D; Koplowitz B; Lee F; McGlinchey K; Qian L; Ricca C; Rovnyak G; Traeger S; Tokarski J; Williams DK; Wu LI; Zhao Y; Manne V; Bhide RS
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1895-9. PubMed ID: 15780629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on farnesyl transferase inhibitors in cancer therapy.
    Mazieres J; Pradines A; Favre G
    Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The up-regulation of vascular endothelial growth factor in mutated Ha-ras HaCaT cell lines is reduced by a farnesyl transferase inhibitor.
    Charvat S; Duchesne M; Parvaz P; Chignol MC; Schmitt D; Serres M
    Anticancer Res; 1999; 19(1A):557-61. PubMed ID: 10226598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.